A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Cho, BC; ...; Zaric, Bojan

Rezultati

eNauka > Rezultati > A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Naziv:	A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
Autori :	Cho, BC; ...; Zaric, Bojan
Godina:	2022
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 33 br. 9 str. S1560-S1560
DOI:	10.1016/j.annonc.2022.10.349
WoS-ID:	000897943700317
URI:	https://enauka.gov.rs/handle/123456789/828158
Projekat:	Yuhan Corporation
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Alt metrika

Dimensions

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.